Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00756262 · ClinicalTrials.gov registry record · Phase 1
Probiotic Lactobacillus GG to Eliminate VRE Colonization
A Phase 1 study, sponsored by Tufts Medical Center.
- Terminated
- Registry status
- Phase 1
- Development phase
- 11
- Enrollment target
NCT00756262 is a Phase 1 study that was terminated before completion, run by Tufts Medical Center. The registered enrollment target is 11 participants.
The verdict
NCT00756262, a Phase 1 study, was terminated before completion, sponsored by Tufts Medical Center.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 11 participants
- Enrollment target
Study Summary
The use of LGG will be associated with elimination of VRE colonization. The primary comparison will be VRE elimination rates among those patients that receive LGG compared to those that receive placebo. The primary endpoint will be the proportion of patients with VRE at one week after cessation of administration of study medication or placebo. The investigators assume that the placebo group will have very little spontaneous elimination of VRE and that the LGG group will be more likely to have eliminated VRE colonization at the end of one week.
Interventions
- BIOLOGICAL Lactobacillus GG or Culturelle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2003-03 |
| Est. Completion | 2012-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00756262
The ClinicalTrials.gov registry entry for NCT00756262 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Tufts Medical Center, which has 169 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Lactobacillus GG or Culturelle is the first listed.
NCT00756262 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00756262 about?
NCT00756262 is a clinical study titled "Probiotic Lactobacillus GG to Eliminate VRE Colonization". The use of LGG will be associated with elimination of VRE colonization. The primary comparison will be VRE elimination rates among those patients that receive LGG compared to those that receive placebo. The primary endpoint will be the proportion of patients with VRE at one week after cessation of ...
What is the current status of trial NCT00756262?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 11 participants. The study started on 2003-03. Estimated completion is 2012-07.
What interventions are being tested in trial NCT00756262?
The interventions under investigation include: Lactobacillus GG or Culturelle (BIOLOGICAL).
Who is sponsoring clinical trial NCT00756262?
This trial is sponsored by Tufts Medical Center, which has 169 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.